Penny’s strong scientific background has led to her specialisation in advising clients in the life sciences sector. She represents clients before the UK patent courts, Court of Appeal and Supreme Court and has represented clients in referrals to the CJEU and EFTA Court.

She has a wealth of experience in co-ordinating multi-jurisdictional patent litigation and has represented clients in European Patent Office opposition and appeal proceedings and in appeals from the UK IPO. Penny also represents clients in patent licence disputes before the UK courts and in arbitration. She is a qualified mediator and a solicitor advocate.

Penny also counsels on patent litigation strategy, including pharmaceutical lifecycle management, and is experienced in providing freedom to operate and due diligence advice.

She is a frequent lecturer on aspects of IP law affecting the life sciences sector and is a tutor on the Oxford University Diploma in Intellectual Property Law and Practice course, teaching patent litigation.

Penny has been a partner at Powell Gilbert since it was founded in 2007.

Key cases

  • Forty Seven v SSB (therapeutic antibodies)

  • Eli Lilly v Eisai (Alzheimer therapies)

  • Mylan v Sandoz (protein purification)

  • Samsung Bioepis & Biogen v AbbVie (adalimumab)

  • GlaxoSmithKline Biologicals v UCB Pharma (vaccines)

  • Icahn School of Medicine at Mount Sinai (SPCs – agalsidase beta)

  • Regeneron v Kymab (antibodies / transgenic mice)

  • Pharmaq v Intervet (SPCs – veterinary vaccine)

  • Eli Lilly v Biogen (monoclonal antibody use)

  • Synageva v CHRF/Shire (orphan drug / enzyme replacement therapy)

  • Eli Lilly v Human Genome Sciences (neutrokine alpha)

  • Eli Lilly v Human Genome Sciences (SPCs – neutrokine alpha)

  • Hospira v Amgen (protein pegylation)

  • Sandoz / ratiopharm v Napp (controlled release oxycodone formulations) 

  • Roche v Chiron (SPCs – trastuzumab and enfuvirtide)

  • Oxford Gene Technology v Affymetrix (DNA microarrays)

  • Pharmacia v Merck (COX 2 inhibitors)

  • Inhale v Quadrant (protein stabilisation)

  • Quadrant v Roser (protein stabilisation)

  • Chiron v Murex & Others (HCV)

  • Chiron v Evans Medical & Others (pertussis antigens)

  • Genentech v Wellcome (tPA)

  • Genentech v Eli Lilly (HGH)